Biotechnology

Friday May 31, 2024 - 2:06 pm

InvestorNewsBreaks – Why Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. “The company’s AVERSA(TM) can be incorporated into any transdermal patch and includes aversive agents to prevent misuse and accidental exposure to drugs with abuse potential, specifically opioids. AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that…

Wednesday May 29, 2024 - 11:54 am

InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) CEO to Present at Jefferies Global Healthcare Conference

Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. The company has announced that its management will present and host one-on-one meetings during the Jefferies Global Healthcare Conference slated to take place in New York City on June 5 and 6, 2024. Vistagen’s Chief Executive Officer Shawn Singh will participate in…

Wednesday May 29, 2024 - 10:30 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO to Participate at Upcoming BIO International Convention 2024

Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, will be spotlighted at next month’s BIO International Convention 2024. The conference is scheduled for June 3–6, 2024, in San Diego. According to the announcement, Predictive Oncology CEO Raymond Vennare will be presenting a company overview at the gathering. His presentation, titled “Novel AI Driven Insights to Guide Early Drug Discovery,” is…

Wednesday May 29, 2024 - 9:43 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Submission of Clinical Trial Protocol for Unbuzzd(TM) Study

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a clinical trial protocol to assess the safety and efficacy of Unbuzzd(TM) in healthy volunteers. The clinical trial protocol for the METAL-2 trial will be reviewed by the U.S. institutional review board. After receiving approval,…

Tuesday May 28, 2024 - 1:11 pm

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Initiates Patient Enrollment in Phase 2 Trial Investigating IGC-AD1

IGC Pharma (NYSE American: IGC) today announced patient enrollment at Neurostudies Inc. in Port Charlotte, Florida, for its Phase 2 clinical trial investigating IGC-AD1 as a potential treatment for agitation in Alzheimer’s disease. According to the announcement, IGC Pharma is currently conducting a Phase 2 trial with IGC-AD1, a partial CB1r agonist with anti-neuroinflammatory properties and an inflammasome inhibitor, to treat agitation in dementia due…

Tuesday May 28, 2024 - 11:55 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Issues Update on NIH-Funded Program for CNM-Au8® in ALS

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has announced several key updates on its National Institutes of Health (“NIH”) funded Accelerating Access to Critical Therapies Expanded Access Program for CNM-Au8® compassionate use (“EAP”) in ALS. Late last year, in…

Tuesday May 28, 2024 - 10:38 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Positive Results from Ovarian Cancer Study

Predictive Oncology (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that positive results from a retrospective study that the company recently completed in collaboration with UPMC Magee-Womens Hospital will be presented at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, which is being held May 31-June 4, 2024, in Chicago. “We would like to thank Brian Orr, MD, lead…

Tuesday May 28, 2024 - 9:09 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters IR Agreement with IR Agency

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into an investor relations services agreement with IR Agency LLC. According to the announcement, the agreement, which was effective May 22, 2024, outlines IR Agency’s responsibilities to communicate information about FSD Pharma to the financial community. That information could include company…

Thursday May 23, 2024 - 9:46 am

InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present Posters at Upcoming ASCP Conference

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, is scheduled to present two posters at this month’s American Society of Clinical Psychopharmacology Conference. The conference is scheduled for May 28–31, 2024, in Miami Beach, Florida. The posters will feature fasedienol, Vistagen’s investigational pherine candidate, which is currently in phase 3…

Wednesday May 22, 2024 - 3:24 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Looking to Transform Healthcare for Individuals with Neurodegenerative Diseases

Clene (NASDAQ: CLNN) has innovated CNM-Au8(R), an oral nanotherapeutic designed to revitalize the brain’s mitochondrial function, which is a significant advancement for the treatment of neurodegenerative disease. “The inspiration for CNM-Au8 comes from the therapeutic potential of elemental metals, a concept understood in both Western and Eastern medicine traditions. Clene’s approach, which leverages nanotechnology, focuses on improving mitochondrial function to support the complex electrical activity…

Wednesday May 22, 2024 - 2:10 pm

InvestorNewsBreaks – SOHM, Inc. (SHMN) Continues to Advance Groundbreaking Technology

SOHM (OTC: SHMN), a leading generic pharmaceutical and upstart biotechnology company, today announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. The technology holds the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The revolutionary new ABBIE system, due…

Wednesday May 22, 2024 - 1:49 pm

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Ensuring Access to Life-Saving Treatments

PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, recently took swift action to address a pressing medical situation unfolding in Malawi, East Africa. "The Ministry of Health (‘MOH’) of Malawi has issued a plea for access to IV suramin, a vital medication in combating the life-threatening sleeping sickness crisis affecting the region. PaxMedica responded to this call for help by…

Wednesday May 22, 2024 - 9:15 am

InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Management Hosting Meetings at Upcoming BIO International Convention 2024

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, will be participating at next month’s BIO International Convention. The four-day event is scheduled for June 3–6, 2024, in San Diego, California. According to the company, members of its management team will be at the conference and will be hosting meetings with pharmaceutical executives. The purpose of the meetings will be to explore partnership and strategic opportunities…

Tuesday May 21, 2024 - 3:30 pm

InvestorNewsBreaks – Astiva Health Fostering Proactive Environment Where Primary Care Thrives

Astiva Health is a leading healthcare provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities. “Astiva Health is dedicated to enhancing the quality of medical care through a strong doctor-patient relationship with the success of its model hinging on knowledgeable, competent and hard-working primary care physicians (‘PCPs’) who play a pivotal role in the healthcare system… Astiva Health is dedicated to…

Tuesday May 21, 2024 - 9:58 am

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Shares ‘Significant Development’ in Depression Study Showing Potential to Extend Remission Period, Prevent Relapse

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, is reporting on results from a study that has identified a potential new drug formulation that could extend the remission period and prevent relapse in individuals dealing with depression. According to the announcement, the study was conducted under Silo Pharma’s sponsored research agreement…

Monday May 20, 2024 - 11:02 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at 2024 Healthcare Company Showcase

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its Chief Executive Officer John Climaco will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners. Climaco’s presentation is slated to begin at 1:40 p.m. ET on…

Monday May 20, 2024 - 10:35 am

InvestorNewsBreaks – NextPlat Corp’s (NASDAQ: NXPL) GTC Begins Sales of SpaceX’s Starlink as Authorized Reseller

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that its subsidiary, Global Telesat Communications Ltd (“GTC”), through a new joint venture agreement with Pivotel Solutions Inc. (dba “Pulsar”) is now a global authorized reseller of SpaceX’s Starlink satellite-based connectivity products. Under the agreement as as an approved reseller, GTC will immediately begin offering Starlink connectivity services in the U.K. and other international markets…

Thursday May 16, 2024 - 11:15 am

InvestorNewsBreaks – HealthLynked Corp. (HLYK) Releases Q1 2024 Financial Results

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced its financial results for the first quarter ended March 31, 2024. During the quarter, the company’s revenue reached $1.0 million, an 8% increase compared to the fourth quarter of 2023, underscoring HealthLynked’s resilience and adaptability in managing transitions while maintaining operational efficiency. The announcement noted HealthLynked’s continued strategic focus on cost control, which saw the…

Thursday May 16, 2024 - 9:45 am

InvestorNewsBreaks – Progressive Care Inc. (RXMD) Releases Q1 2024 Financial Report Showing Record Revenue

Progressive Care (OTCQB: RXMD), a personalized healthcare services and technology provider, is reporting financial results for first quarter 2024, the period ended March 31, 2024. Highlights of the report show the company saw record first-quarter revenues of an estimated $14 .6 million, a 28% increase over revenues reported in the first quarter of 2023, as well as growth in its contract services space. The report also noted that…

Wednesday May 15, 2024 - 3:30 pm

InvestorNewsBreaks – Why HealthLynked Corp. (HLYK) Is ‘One to Watch’

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, is revolutionizing patient care through innovative digital solutions. “With a commitment to leveraging its advanced technology platforms, HealthLynked employs a sophisticated, cloud-based network that serves as a comprehensive repository for personal health data. This system not only simplifies the management and archiving of medical records but also enables the application of AI to deliver personalized healthcare insights.…

Wednesday May 15, 2024 - 3:14 pm

InvestorNewsBreaks – Astiva Health Reshaping Personalized and Comprehensive Healthcare Landscape

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, has always been working on improving its provider network and physician-patient relationships, ensuring health plans align with client needs and directives. “It is this [physician-patient] partnership that Astiva is implementing in its groundbreaking approach to creating a dynamic and innovative Medicare Advantage Prescription Drug (‘MAPD’) health plan…

Wednesday May 15, 2024 - 1:07 pm

InvestorNewsBreaks — PaxMedica Inc. (PXMD) Appeals NASDAQ Delisting Decision, Prepares for June FDA Meeting

PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has filed a formal notice of appeal with the NASDAQ Office of Appeals and Review; the company is appealing to reverse the decision of the NASDAQ Hearings Panel to delist the company from. The company also announced that it has retained Jacob Frenkel, Dickinson Wright, PLLC as its lead counsel in the…

Wednesday May 15, 2024 - 12:12 pm

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces Q1 2024 Financial Results

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, today announced financial results for the first quarter ended March 31, 2024. During the quarter, the company reported a loss from operations of $629,972, as compared to an operating loss of $521,258 for the comparable period in 2023. Sigyn Therapeutics’ net loss for Q1 2024 was $758,088 or $0.62 per share, as compared to a net…

Wednesday May 15, 2024 - 11:28 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Releases Financial Report, Business Update for Q1 2024

Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, is reporting financial results and a business update for the first quarter of 2024, the period ended March 31, 2024. Highlights of the report include that the company’s phase 2b clinical trial evaluating Lomecel-B(TM) in rare pediatric disease hypoplastic left heart syndrome (“HLHS”) is on track for completing…

Wednesday May 15, 2024 - 11:20 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Q1 2024 Financial Results, Provides Business Update

Predictive Oncology (NASDAQ: POAI) is a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development. The company today announced financial and operating results for the quarter ended March 31, 2024, and provided a corporate update. The company reported a net loss of approximately…

Wednesday May 15, 2024 - 10:30 am

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Q1 2024 Results

DarioHealth (NASDAQ: DRIO), a leader in the global digital health market, today reported financial results for the first quarter 2024. Among the highlights, the company reported first quarter revenue of $5.8 million, reflecting a 59% increase over the fourth quarter of 2023 primarily resulting from an increase in B2B2C revenues. “In the first quarter, our revenue increased by 59% over the fourth quarter 2023 reflecting…

Tuesday May 14, 2024 - 1:07 pm

InvestorNewsBreaks – Rejuvine Life Sciences Launches Crowdfunding Campaign

Rejuvine Life, dedicated to developing natural healthcare solutions, today announced a crowdfunding campaign to expand its U.S. product line and advance diabetes research management. According to the announcement, the company utilizes natural resources to support the millions worldwide living with diabetes. Skordo Plus, Rejuvine Life’s leading product, is a garlic-based supplement designed to help regulate blood sugar levels and enhance overall well-being. “We believe everyone…

Tuesday May 14, 2024 - 12:49 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation Schedule for Upcoming May Conferences

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced that it will participate in three investor conferences in May. Clene will participate in one-on-one meetings at the Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual…

Tuesday May 14, 2024 - 12:35 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Participation in FDA Event Exploring Emerging Therapeutic Interest in Ketamine

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced its planned attendance at a hybrid public meeting on June 27, 2024. The meeting will be hosted by the U.S. Food and Drug Administration (“FDA”) in partnership with the Reagan-Udall Foundation for the FDA. The virtual and in-person event,…

Tuesday May 14, 2024 - 12:23 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q3 Fiscal 2024 Financial Results, Business Update

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, is reporting on its financial and business results for the third quarter of 2024, the period that ended March 31, 2024. Business highlights included the announcement of preclinical data supporting both the company’s INM-901 and INM-089 programs; the continued development of its ALZ program, with long-term…

Tuesday May 14, 2024 - 12:02 pm

InvestorNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) Highlights Innovation in Beverage Wellness, Expands to the Northeast

Safety Shot (NASDAQ: SHOT) is a pioneering force in the beverage landscape, introducing a groundbreaking solution designed to swiftly alleviate the effects of alcohol consumption. With its patented formula, Safety Shot accelerates the detoxification process, offering consumers a rapid path to relief and reshaping nocturnal revelries and morning recoveries. By leveraging a carefully crafted blend of scientifically proven ingredients, including vitamins, minerals and nootropics, Safety…

Tuesday May 14, 2024 - 11:00 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Slated to Present at Upcoming Alliance Global Partners Healthcare Company Showcase

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, will be participating in an upcoming virtual Alliance Global Partners Healthcare Company Showcase. The event is scheduled for May 21, 2024. According to the announcement, Cybin CEO Doug Drysdale will be presenting a fireside chat during the showcase; his presentation…

Tuesday May 14, 2024 - 9:45 am

InvestorNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Releases Q3 202 Financial Report

Astrotech (NASDAQ: ASTC), an innovative science and technology company, is reporting its financial results for the third quarter of fiscal year 2024, for the period ended March 31, 2024. Highlights of the report include the company’s strong consolidated balance sheet showing $34.7 million in cash and liquid investments; revenue for the year-to-date coming in at $1.6 million; year-to-date gross margin increased to 45% from 37% through…

Monday May 13, 2024 - 11:18 am

InvestorNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) AIMIGo(TM) Recognized as ‘Best New ECG Technology Solution’ in Awards Program

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced that its HeartBeam AIMIGo(TM) was selected as winner of the “Best New ECG Technology Solution” award in the 8th annual MedTech Breakthrough Awards program. Conducted by MedTech Breakthrough, an independent market intelligence organization, the awards program recognizes the top companies, technologies and products in the…

Monday May 13, 2024 - 9:26 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Releases Planned Transitions for Board of Directors

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, is reporting changes on its board of directors. The following transitions on the board have been announced: Richard Kender, retired SVP of business development and corporate licensing for Merck & Co. Inc., has been appointed to the board; Dr. Roger Hajjar, former head of R&D at Ring Therapeutics, and…

Friday May 10, 2024 - 1:57 pm

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Featured in Upcoming RedChip Small, Big Money(TM) Show

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is featured in an upcoming interview on the RedChip Small Stocks, Big Money(TM) show. During the program, which is scheduled to air on Bloomberg TV this Saturday, May 11, at 7 p.m. ET, Gareth Sheridan, Founder and CEO of Nutriband, will provide a corporate update. To access the interview, visit https://ibn.fm/Nhihy To…

Friday May 10, 2024 - 9:14 am

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q1 2024 Financial, Operational Report

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, is reporting on its financial and operational results for first quarter 2024, for the period ended March 31, 2024. Highlights of the report include the 510(k) submission for BEAT’s AIMIGo(TM) system for review by the U.S. Food and Drug Administration (“FDA”); presubmission meetings being held with the…

Thursday May 09, 2024 - 3:35 pm

InvestorNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Filling Void in Hemp and Cannabis Market

Astrotech (NASDAQ: ASTC), a science and technology development and commercialization company, and its wholly owned subsidiary, AgLAB Inc., have developed a mass spectrometer designed for use in the hemp and cannabis market. “During the process of converting cannabis biomass into distillate, valuable cannabinoids are typically lost, resulting in reduced profits. AgLAB’s Maximum Value Processing (‘MVP’) method uses the powerful AgLAB-1000-D2 mass spectrometer to test and…

Wednesday May 08, 2024 - 12:44 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Releases Q1 2024 Financial Numbers, Operation Highlights

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., are reporting on first-quarter 2024 financial results and operating highlights for its CNM-Au8 clinical program for amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). Clene Nanomedicine is a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases. Highlights of the report include the news that data from the long-term extension of…

Tuesday May 07, 2024 - 11:57 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Marks Important Step in Advancing Lucid-21-302

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces the submission to ethics of a trial. Entitled “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants,” the clinical trial application is…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions